Follicular drug reaction from cetuximab. A common side effect in the treatment of metastatic colon carcinoma;Follikuläre arzneimittelreaktion auf cetuximab. Eine häufige nebenwirkung bei der therapie metastasierter kolorektaler karzinome

Hautarzt

Volumn 57, Issue 8, 2006, Pages 701-704

  Braun Falco, M ^a   Holtmann, C ^a   Lordick, F ^a   Ring, J ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Anti cancer therapy; Cetuximab; EGF R inhibition; Exanthematous drug eruption; Side effects

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUCOCORTICOID RECEPTOR BETA;

ADULT; ARTICLE; CANCER INHIBITION; CANCER THERAPY; CASE REPORT; COLON CARCINOMA; DARIER DISEASE; DRUG ERUPTION; FOLLICULITIS; HOMEOSTASIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; METASTASIS; SEBORRHEIC DERMATITIS; SKIN APPENDAGE; TUMOR GROWTH;

ANAPHYLAXIS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLONIC NEOPLASMS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG ERUPTIONS; FOLLICULITIS; HUMANS; INFUSIONS, INTRAVENOUS; LIVER NEOPLASMS; MALE; MIDDLE AGED; SKIN;

EID: 33748920171     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00105-005-0979-5     Document Type: Article

References (14)

1. Busam KJ, Capodieci P, Motzer R et al. (2001) Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 144:1169-1176
2. Cunningham D, Humblet Y, Siena S et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345
3. El-Rayes EF, LoRusso PM (2004) Targeting the epidermal growth factor receptor. Br J Cancer 91:418-424
4. Fernadez-Galar M, Espana A, Lopez-Picazo JM (2004) Acneiform lesions secondary to ZD1839, an inhibitor of the epidermal growth factor receptor. Clin Exp Dermatol 29:138-140
5. Khorana AA, Ryan CK, Cox C et al. (2003) Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with stage II and III colon carcinoma: a role for host response in prognosis. Cancer 97:960-968
6. Lee MW, Seo CW, Kim SW et al. (2004) Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor. Acta Dermatol Venereol 84:23-26
7. Murillas R, Larcher F, Conti CJ et al. (1995) Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure. EMBO J 14:5216-5223
8. Nanney LB, Magid M, Stoscheck CM, King LE (1984) Comparison of epidermal growth factor binding and receptor distribution in normal human epidermis and epidermal appendages. J Invest Dermatol 83:385-393
9. Onn A, Tsuboi M, Thatcher N (2004) Treatment of non-small-cell lung cancer: a perspective on the recent advances and the experiences with gefitinib. Br J Cancer 91 [Suppl 2]:S11-17
10. Perez-Soler R (2003) Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology 17 [Suppl 12]:23-28
11. Perez-Soler R, Chachoua A, Hammond LA et al. (2004) Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22:3238-3247
12. Peus D, Hamacher L, Pittelkow MR (1997) EGF-receptor tyrosine kinase inhibition induces keratinocyte growth arrest and terminal differentation. J Invest Dermatol 109:751-756
13. Salz LB, Meropol NJ, Loehrer PJ et al. (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201-1208
14. Vanhoefer U (2003) Neue molekulare Ansätze in der Therapie des fortgeschrittenen kolorektalen Karzinoms. Onkologie 26 [Suppl 7]:70-74